What is integrin-linked kinase?
Integrin-linked kinase (ILK) is a serine/threonine kinase that associates with the cytoplasmic tail of β-integrin receptors and couples integrin engagement to downstream signalling pathways including PI3K-Akt and cell-survival cascades. The published mechanism arm for TB-500 in cardiac and endothelial cell models.
What the research literature says
ILK is a multidomain protein with a kinase domain, an ankyrin-repeat domain, and a pleckstrin-homology-like domain. It binds the cytoplasmic tail of β1 and β3 integrins at focal adhesions, where it functions both as a scaffolding protein (coordinating recruitment of downstream signalling effectors) and as a kinase (phosphorylating substrates including PKB/Akt and GSK-3β).
The Bock-Marquette work characterised thymosin β4 activation of integrin-linked kinase as the central mechanism driving cardiac cell migration, survival, and cardiac repair in their preclinical model (PMID 15565145). This finding established ILK as a key mechanism arm for TB-500 pharmacology in cardiac and broader connective-tissue research contexts. The Hinkel cardiac-repair review extends the framework into the broader cardiac-research literature (PMID 22236126).
The ILK arm operates in parallel with the actin-binding pharmacology characterised in the Yarmola ternary-complex work (PMID 11579089) — both mechanism arms contribute to TB-500’s published activity profile, with the ILK arm more relevant to receptor-mediated downstream signalling and the actin-binding arm more relevant to cytoskeletal-substrate availability.
Why this matters in research context
Integrin-linked kinase matters in peptide-research contexts primarily as the published mechanism arm for TB-500’s effects on cardiac and endothelial cell biology. Researchers studying TB-500 pharmacology should distinguish between the actin-binding arm (primary mechanism characterised in the original Yarmola work) and the integrin-linked kinase arm (characterised in subsequent cardiac-research literature).
Related compounds
- TB-500 10mg — ILK activation as the published cardiac-research mechanism
Related research questions
References
- Yarmola EG et al. Formation and implications of a ternary complex of profilin, thymosin beta 4, and actin. J Biol Chem 2001;276(49):46094-46101. [PMID 11579089]
- Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-472. [PMID 15565145]
- Dubé KN et al. Thymosin β4 protein therapy for cardiac repair. Curr Pharm Des 2012;18(6):813-817. [PMID 22236126]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.